Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivutamab
- Development stage
- Unknown
- Lead developer
- Shanghai Sailon Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Amivutamab (SL-101) is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Developed by Shanghai Sailon Biotechnology, it is specifically being evaluated for the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC) who have progressed after standard therapies. The antibody binds to the extracellular domain of EGFR, preventing the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). This blockade inhibits the activation of intracellular signaling cascades, including the MAPK and PI3K/Akt pathways, which are critical for tumor cell proliferation, survival, and angiogenesis. As a fully human antibody, amivutamab is designed to offer a favorable safety profile with potentially lower immunogenicity compared to chimeric anti-EGFR agents like cetuximab.
- Other names
- amivutamab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on amivutamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivutamab.